PERNIX THERAPEUTICS HOLDINGS, INC.
PERNIX THERAPEUTICS HOLDINGS, INC. (PTX): 3 pipeline candidates · ~9 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.2 months
D/E -2.18 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for PERNIX THERAPEUTICS HOLDINGS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$24.5M
Quarterly Burn
$17.3M
Runway
9.2 mo
Revenue
$37.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| silenor | Approved |
| treximet | Approved |
| zohydro er with beadtek | Approved |
Frequently asked questions
How many drug candidates are in PERNIX THERAPEUTICS HOLDINGS, INC.'s pipeline?
PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PERNIX THERAPEUTICS HOLDINGS, INC.'s lead drug candidate?
PERNIX THERAPEUTICS HOLDINGS, INC.'s most advanced tracked candidate is silenor (Approved) for insomnia characterized by difficulty with sleep maintenance.
What is PERNIX THERAPEUTICS HOLDINGS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PERNIX THERAPEUTICS HOLDINGS, INC. has approximately 9.2 months of cash runway.
Get the full picture on PERNIX THERAPEUTICS HOLDINGS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.